Revenue (Tables)

6 Months Ended

Jun. 30, 2023

Revenue from Contract with Customer [Abstract]

Schedule of Disaggregation of Revenue

The following table presents the approximate percentage of our net sales by market group:

	Three Months Ended June 30,		Six Months Ended June 30,
	2023	2022	2023	2022
Biologics	37 %	43 %	36 %	43 %
Generics	20 %	18 %	20 %	17 %
Pharma	25 %	24 %	26 %	24 %
Contract-Manufactured Products	18 %	15 %	18 %	16 %
	100 %	100 %	100 %	100 %

The following table presents the approximate percentage of our net sales by product category:

	Three Months Ended June 30,		Six Months Ended June 30,
	2023	2022	2023	2022
High-Value Product Components	49 %	57 %	50 %	56 %
High-Value Product Delivery Devices	12 %	5 %	10 %	5 %
Standard Packaging	21 %	23 %	22 %	23 %
Contract-Manufactured Products	18 %	15 %	18 %	16 %
	100 %	100 %	100 %	100 %

Due to the Company's reassessment of product categories, beginning in the second quarter of 2023 certain product types have been moved from High-Value Product Components to High-Value Product Delivery Devices. No adjustments were made to the product categorization prior to the second quarter of 2023.

The following table presents the approximate percentage of our net sales by geographic location:

	Three Months Ended June 30,		Six Months Ended June 30,
	2023	2022	2023	2022
Americas	44 %	47 %	44 %	46 %
Europe, Middle East, Africa	46 %	45 %	47 %	45 %
Asia Pacific	10 %	8 %	9 %	9 %
	100 %	100 %	100 %	100 %

Schedule of Change in Contract with Customer, Asset and Liability

The following table summarizes our contract assets and liabilities:

	($ in millions)
Contract assets, December 31, 2022	$	16.3
Contract assets, June 30, 2023	21.4
Change in contract assets - increase (decrease)	$	5.1
Deferred income, December 31, 2022	$	(68.2)
Deferred income, June 30, 2023	(56.7)
Change in deferred income - decrease (increase)	$	11.5